Bayerische Motoren Werke ADR (BMWYY)

DeKalb, IL - April 10, 2026 - Motor Works, DeKalb's trusted auto repair facility since 1984, continues to redefine what it means to be a dealership alternative in a college town where several major automotive brands have no local representation. Under the leadership of owner Meghan Huber, who purchased the business from her father five years ago, Motor Works has experienced explosive growth while maintaining the family-friendly, education-first approach that has made it a community staple trusted by DeKalb families.

First-quarter sales for U.S. automakers were rough, but Ford had one significant decline that could be costly.

After seven years of annual sales declines, Stellantis investors are desperate for sales to gain traction and drive results higher. Here's the good news.

The immune system is capable of identifying and attacking cancer cells in the body. This process depends on the tumor producing damaged RNA, which then sticks to cell surfaces and provides the antigens that the body identifies as foreign and therefore targets. However, a natural mechanism within the body that removes faulty RNA ironically aids many cancers to avoid detection and therefore limit immune system responses to the disease.

LIXTE Biotechnology (NASDAQ: LIXT) is executing a differentiated strategy in oncology, extending beyond traditional drug development into a more integrated and multi-dimensional approach to cancer care. With the company’s lead clinical candidate, LB-100, advancing through trials and the addition of Liora Technologies to its platform, they are positioning themselves at the nexus of pharmaceutical innovation and next-generation radiotherapy ( ibn.fm/C7Kms ).

Cardio Diagnostics Holdings (NASDAQ: CDIO), a precision cardiovascular medicine company leveraging epigenetics, genetics and artificial intelligence, has engaged IBN to support its corporate communications strategy as it advances blood-based solutions for the prevention and detection of cardiovascular disease. The company develops and commercializes clinical tests and data platforms that integrate molecular biomarkers with AI to generate patient-specific insights, including Epi+Gen CHD(TM), a prescription-only test for assessing three-year coronary heart disease risk, PrecisionCHD(TM) for detection and management, HeartRisk(TM) for population-level intelligence and CardioInnovate360(TM) to support cardiovascular therapy development.

Cancer research is crucial for understanding, diagnosing, treating, and preventing the disease. However, this research often relies on large and complex biomedical datasets, which are often incredibly difficult and time-consuming to go through manually.

Researchers at the University of Calgary in Canada are conducting further trials after early studies revealed that vitamin B3, or niacin, holds promise in restoring immune function in the fight against glioblastoma, a brain cancer that grows aggressively and is hard to treat.

Disseminated on behalf of MindBio Therapeutics Corp. (CSE: MBIO) (OTCQB: MBQIF) and may include paid advertising.

According to a poll conducted by Gallup in March, Americans are most concerned about healthcare . This finding is notable given the escalation in the Iran war and the way events in the Middle East are currently dominating news headlines.

Electric vehicles (EVs) are taking over roads worldwide, but charging them can be tricky when traveling between regions with different standards. That’s where the CCS2-GBT V2 400A adapter comes in. Designed by a leading EV charger solution factory, this powerful adapter lets you charge GB/T-compatible cars like the Zeekr 001, BMW i3, and Avarta at ultra-fast CCS2 stations—no more worrying about incompatible plugs or slow charging speeds.

A recently published report by Mordor Intelligence analyzes future projections, growth drivers and the key trends that are shaping the rapidly growing market for cancer immunotherapy. The report puts the valuation of this market in 2025 at $144.8 billion and projects that it will expand to $311.4 billion by 2031.

For off-road enthusiasts dreaming of the ultimate European adventure, Enduro Park Isábena stands out as a top destination. Nestled in the heart of the Spanish Pyrenees, this certified BMW Motorrad off-road center offers everything needed to experience enduro at its best — breathtaking landscapes, professional guides, and the freedom to explore Europe on two wheels.

Excellent brake pads, not only excellent braking performance, but also has the characteristics of braking comfort, brake pads do not hurt discs, wheels do not fall dust. The advantages and disadvantages of brake pads determines the size of the vibration generated by the brake pads during braking, serious noise pollution, affecting the comfort of members and even physical and mental health, but also cause fatigue damage to automotive parts, buried brake failure and other dangers.

The publication of clinical research in peer-reviewed journals remains a critical milestone in drug development, offering independent validation and broader visibility for emerging therapies. Soligenix (NASDAQ: SNGX) recently reached such a milestone with the publication of a clinical summary of its HyBryte(TM) therapy, reinforcing the importance of scientific transparency as the company advances treatments for rare diseases.

QIAPO, involving BMW and Infineon, validates hybrid quantum-classical computing. UK startup Quantum Links AI offers a commercial platform routing workloads between classical and quantum systems, integrating with AWS and IBM to deliver real-world enterprise benefits.

LIXTE Biotechnology Holdings (NASDAQ: LIXT), a clinical-stage pharmaceutical company, is in the unique position of holding the world’s only clinical-stage protein phosphatase 2A (“PP2A”) inhibitor, called LB-100.

A team of scientists from Texas Children’s Hospital, University of Pittsburgh and Baylor College of Medicine has discovered the primary driver of a deadly pediatric brain cancer, PFA (posterior fossa type A) ependymoma. They identified male sex hormones called androgens as playing a key role in promoting PFA ependymoma growth.

Nutriband (NASDAQ: NTRB) announced it has selected a proposed worldwide brand name for its abuse-deterrent fentanyl transdermal system, with plans to submit the name and product labeling to the FDA and international regulators as well as file for trademark protection. The company said the product, developed using its AVERSA(TM) technology, could become the first abuse-deterrent fentanyl patch designed to reduce misuse and accidental exposure, targeting a potential peak annual U.S. market of $80 million to $200 million while addressing broader global pain management needs.

Lantern Pharma (NASDAQ: LTRN) reported fourth-quarter and full-year 2025 operational highlights led by continued progress in its LP-300 Phase 2 HARMONIC trial, completion of targeted enrollment in Japan, planned protocol discussions with the FDA in mid-May 2026 and advancement of LP-184, LP-284 and STAR-001 across multiple oncology indications. The company said its AI-driven portfolio now targets an estimated annual market opportunity of more than $15 billion, while its RADR(R) platform and newly introduced withZeta.ai multi-agentic co-scientist platform are expanding commercial potential, with beta testing underway at more than 25 biotech companies, cancer research centers and biopharma consultants, as Lantern ended 2025 with approximately $10.1 million in cash, cash equivalents and marketable securities.

Modern problems require modern solutions, and that's what Detroit automakers are currently figuring out in China.

Researchers seeking new ways of fighting cancer using immunotherapy have discovered a “hidden brake” that had previously been unknown to scientists. This brake exists on immune cells and scales back their ability to combat cancer, and it acts without any influence from tumor cells.

Lixte Biotech Holdings (NASDAQ: LIXT) is advancing the frontiers of precision oncology, developing therapies that complement existing cancer treatments while integrating cutting-edge data solutions. The company’s lead program, LB-100, is a novel small-molecule compound designed to enhance the efficacy of chemotherapy and radiation, aiming to improve patient outcomes while reducing treatment-related side effects. By focusing on improving the therapeutic index of existing cancer modalities, the company is tackling a recurrent challenge in the field of oncology: maximizing treatment impact while cutting down risks to healthy tissue.

NextPlat (NASDAQ: NXPL, NXPLW) announced a collaboration with HealthWarehouse.com Inc. (OTCQB: HEWA) to enable nationwide fulfillment of prescription and over-the-counter products, significantly expanding its U.S. healthcare footprint beyond Florida. The partnership allows NextPlat’s PharmcoRx division to deliver medications across all 50 states through HealthWarehouse’s licensed digital pharmacy platform, supporting broader e-commerce expansion and positioning the company to scale revenue growth and healthcare access in 2026.